Verona Pharma plc
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pu… Read more
Verona Pharma plc (I9SA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.110x
Based on the latest financial reports, Verona Pharma plc (I9SA) has a cash flow conversion efficiency ratio of 0.110x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€30.56 Million) by net assets (€278.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Verona Pharma plc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Verona Pharma plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Verona Pharma plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Verona Pharma plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bank of Ningbo Co Ltd
SHE:002142
|
0.008x |
|
RPM International Inc
NYSE:RPM
|
0.110x |
|
A.P. Møller - Mærsk A/S
PINK:AMKBF
|
0.050x |
|
Check Point Software Technologies Ltd
NASDAQ:CHKP
|
0.122x |
|
Smith & Nephew plc
PINK:SNNUF
|
0.076x |
|
TCEYF
PINK:TCEYF
|
0.051x |
|
Watsco Inc
NYSE:WSO
|
0.108x |
|
Affirm Holdings Inc
NASDAQ:AFRM
|
0.049x |
Annual Cash Flow Conversion Efficiency for Verona Pharma plc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Verona Pharma plc from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €204.56 Million | €-122.20 Million | -0.597x | -196.53% |
| 2023-12-31 | €249.28 Million | €-50.22 Million | -0.201x | +22.44% |
| 2022-12-31 | €230.47 Million | €-59.86 Million | -0.260x | -15.61% |
| 2021-12-31 | €148.00 Million | €-33.25 Million | -0.225x | +7.86% |
| 2020-12-31 | €184.85 Million | €-45.08 Million | -0.244x | +74.74% |
| 2019-12-31 | €44.40 Million | €-42.87 Million | -0.965x | -325.69% |
| 2018-12-31 | €79.86 Million | €-18.11 Million | -0.227x | -18.30% |
| 2017-12-31 | €107.95 Million | €-20.70 Million | -0.192x | -45.96% |
| 2016-12-31 | €42.53 Million | €-5.59 Million | -0.131x | -- |